See more : Beijing Jingneng Power Co., Ltd. (600578.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Poseida Therapeutics, Inc. (PSTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Poseida Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- OC Oerlikon Corporation AG (OERLF) Income Statement Analysis – Financial Results
- FoxWayne Enterprises Acquisition Corp. (FOXWW) Income Statement Analysis – Financial Results
- Sandoz Group AG (SDZ.SW) Income Statement Analysis – Financial Results
- JEOL Ltd. (6951.T) Income Statement Analysis – Financial Results
- Enel Chile S.A. (ENELCHILE.SN) Income Statement Analysis – Financial Results
Poseida Therapeutics, Inc. (PSTX)
About Poseida Therapeutics, Inc.
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates. It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 64.70M | 130.36M | 31.24K | 0.00 | 0.00 | 0.00 | 2.99M | 9.77M |
| Cost of Revenue | 156.77M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 0.00 | 0.00 |
| Gross Profit | -92.07M | 125.19M | -4.52M | -2.59M | -1.19M | -689.00K | 2.99M | 9.77M |
| Gross Profit Ratio | -142.29% | 96.03% | -14,472.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% |
| Research & Development | 156.77M | 152.90M | 136.73K | 103.52K | 60.39M | 30.88M | 19.10M | 9.86M |
| General & Administrative | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.35M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -220.00K |
| SG&A | 37.44M | 37.54M | 35.92K | 23.03K | 18.46M | 9.67M | 5.48M | 5.13M |
| Other Expenses | 0.00 | 2.86M | 19.80K | 280.00 | 2.56M | -821.00K | 37.00K | 0.00 |
| Operating Expenses | 194.21M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.00M |
| Cost & Expenses | 179.35M | 190.44M | 172.65K | 126.55K | 78.85M | 40.56M | 24.58M | 15.22M |
| Interest Income | 0.00 | 6.37M | 3.36M | 3.51M | 1.55M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.67M | 6.37M | 3.36K | 3.51K | 3.55M | 1.80M | 558.00K | 0.00 |
| Depreciation & Amortization | 5.61M | 5.17M | 4.55M | 2.59M | 1.19M | 689.00K | 676.00K | 220.00K |
| EBITDA | -109.04M | -54.77M | -117.06M | -145.48M | -91.68M | -45.12M | -20.88M | -5.12M |
| EBITDA Ratio | -168.52% | -43.79% | -389.32% | 0.00% | 0.00% | 0.00% | -699.50% | -53.53% |
| Operating Income | -129.50M | -59.95M | -141.41K | -126.55K | -85.53M | -41.99M | -19.67M | -5.45M |
| Operating Income Ratio | -200.15% | -45.98% | -452.69% | 0.00% | 0.00% | 0.00% | -658.89% | -55.78% |
| Total Other Income/Expenses | 6.18M | -3.51M | 16.44M | -129.65M | -7.68M | -2.62M | 1.40M | 109.00K |
| Income Before Tax | -123.32M | -63.46M | -124.97K | -129.78K | -86.53M | -44.61M | -20.19M | -5.34M |
| Income Before Tax Ratio | -190.60% | -48.68% | -400.07% | 0.00% | 0.00% | 0.00% | -676.35% | -54.67% |
| Income Tax Expense | 107.00K | 544.00K | -4.53M | -2.58M | 6.11M | -202.00K | -527.00K | -765.00K |
| Net Income | -123.43M | -64.00M | 4.40M | 2.45M | -92.64M | -44.40M | -19.66M | -4.58M |
| Net Income Ratio | -190.76% | -49.10% | 14,097.81% | 0.00% | 0.00% | 0.00% | -658.69% | -46.84% |
| EPS | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| EPS Diluted | -1.37 | -0.89 | 0.07 | 0.07 | -2.33 | -1.24 | -0.49 | -0.08 |
| Weighted Avg Shares Out | 90.19M | 71.91M | 62.18M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
| Weighted Avg Shares Out (Dil) | 90.19M | 71.95M | 62.24M | 36.00M | 39.73M | 35.93M | 39.73M | 59.32M |
Poseida Therapeutics to Present Preclinical Data Highlighting Fully Allogeneic CAR-T Product Candidates at the Society for Immunotherapy of Cancer 2021 Annual Meeting
Wall Street Analysts Predict a 281% Upside in Poseida Therapeutics, Inc. (PSTX): Here's What You Should Know
Poseida Therapeutics: Genome Engineering For Safer Cell Therapies
A new deal with Takeda could mean up to $3.6 billion in milestone payments for Poseida Therapeutics
Poseida's Solid Tumor CAR-T Candidate Data Fails To Impress Investors
Poseida Therapeutics Presents Preliminary Results from Phase 1 Trial of P-PSMA-101 at the 6th Annual CAR-TCR Summit
Poseida's Fully Allogeneic CAR-T Product Enters Human Trial For Multiple Myeloma
Poseida Therapeutics Announces FDA Clearance of Investigational New Drug Application for P-BCMA-ALLO1, an Allogeneic CAR-T Candidate for Relapsed/Refractory Multiple Myeloma
New Strong Sell Stocks for August 27th
Poseida Therapeutics Announces Virtual 2021 Annual Meeting of Stockholders
Source: https://incomestatements.info
Category: Stock Reports